Wilson Sonsini Advises Transcarent on $58 Million Series B Funding

On June 10, 2021, Transcarent, a consumer-directed health and care experience for employees of self-insured employers and their families, announced a $58 million Series B investment led by General Catalyst and 7wireVentures, with participation from Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures, and Threshold Ventures, along with existing investors Alta Partners and Jove Equity Partners.

The financing round brings Transcarent’s total funding to $98 million and will allow the company to respond to the demand for rapid expansion of its innovative risk-based offering for self-insured employers.

A Wilson Sonsini Goodrich & Rosati team that included Mark Baudler, Jonathan Chan, Ashley Yueh, Rowena Chen, and Hayoung Kim represented Transcarent in the transaction.

For more information, please see Transcarent's press release. Further coverage can be found at Fierce Healthcare.